eFFECTOR Therapeutics, Inc. (NASDAQ:EFTRW) Short Interest Update

eFFECTOR Therapeutics, Inc. (NASDAQ:EFTRW) was the recipient of a significant growth in short interest in April. As of April 15th, there was short interest totalling 10,700 shares, a growth of 148.8% from the March 31st total of 4,300 shares. Based on an average daily volume of 30,800 shares, the short-interest ratio is presently 0.3 days.

eFFECTOR Therapeutics Price Performance

EFTRW traded down $0.01 during trading on Friday, reaching $0.03. 28,014 shares of the stock were exchanged, compared to its average volume of 30,854. The stock’s 50 day moving average price is $0.11 and its two-hundred day moving average price is $0.12. eFFECTOR Therapeutics has a twelve month low of $0.02 and a twelve month high of $0.21.

eFFECTOR Therapeutics Company Profile

eFFECTOR Therapeutics, Inc, a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer.